Clinical trials: First-Episode Psychosis
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia and Disorders With Psychotic Features
Specialized Treatment Early in Psychosis (STEP)
The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis.
- Trial name
- STEP (NCT00309452)
- Testing
- Cognitive Behavioral Group Therapy, Cognitive remediation, Medications
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Yale University
Cannabis-Related Disorder, Substance-Related Disorders
First Episode Schizophrenia and Cannabis-Related Disorder Study
Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response.
- Conditions
- Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
- Trial name
- NCT00573287
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Psychosis
Minnesota Community-Based Cognitive Training in Early Psychosis
The purpose of this study is to determine whether cognitive training exercises can improve cognitive functioning in young patients with recent-onset psychosis who are being treated in community mental health settings using the…
- Conditions
- Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- Mini-COTES (NCT03079024)
- Testing
- Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Minnesota
Schizophrenia, Schizophreniform Disorder
DECIFER: Depression and Citalopram In First Episode Recovery
This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients.
- Trial name
- DECIFER (NCT01041274)
- Testing
- Citalopram, Psychoeducation, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Schizophrenia, Schizophreniform Disorders
Horyzons: Implementation and Integration in Clinical Practice
The primary aim of this trial is evaluating the barriers and enablers of implementing a digital intervention with both therapeutic content and social networking, Horyzons, as part of clinical care in first episode psychosis (FEP)…
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
- Trial name
- NCT06002958
- Testing
- Horyzons USA
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Metabolic Signatures and Biomarkers in Schizophrenia
We plan to use a metabolomics lipid platform to map biochemical signatures in unmedicated schizophrenic patients prior to and 4 weeks post treatment with the antipsychotic drug aripiprazole and compare that to lipid perturbations…
- Trial name
- NCT00466310
- Testing
- Aripiprazole, Risperidone, Healthy volunteers
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Duke University
Schizophrenia, First Episode Psychosis
Using Digital Media Advertising to Reduce the Duration of Untreated Psychosis
There is compelling evidence that longer duration of untreated psychosis independently predicts negative outcomes. The proposal aims to explore whether targeted and proactive online outreach through search engine advertisements…
- Trial name
- NCT03975400
- Testing
- search engine advertisement campaign
- Where
- 2 sites in United States
- Volunteers
- 698 people
- Sponsor
- Northwell Health
First-Episode Psychosis
Clinical Interviews With Detainees With Early Psychosis
The investigators are studying a jail-based intervention to reduce the duration of untreated psychosis (DUP) among young adults with previously undetected first-episode psychosis who are detained in jail.
- Trial name
- Interview (NCT03962348)
- Testing
- Specialized Early Engagement Support Service
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Psychosis, First Episode Psychosis
Feasibility of an Early Detection Program for Early Psychosis on a College Campus
The objective of the proposed study is to determine the feasibility of an Early Detection program that aims to: (i) identify college students at clinical high risk (CHR) of psychosis or with first episode psychosis (FEP), and…
- Conditions
- Psychosis, First Episode Psychosis, Clinical High Risk for Psychosis
- Trial name
- NCT03983421
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Schizophrenia, Schizoaffective Disorder, Depressive Type
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
- Trial name
- APPRAISE (NCT04203056)
- Testing
- Aripiprazole Lauroxil, ARI-ORAL, AL-NCD
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Los Angeles
First Episode Psychosis
Artificial Intelligence to Measure Adherence to Oral Medication
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
- Trial name
- NCT04046497
- Testing
- Smartphone App, Usual Care
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Northwell Health
Schizophrenia, Schizophreniform Disorder
rTMS in First Episode Psychosis
This study proposes to examine the application of rTMS for the treatment of cognitive dysfunction in FEP. This is an important population for study because if effective, rTMS may represent a preventative treatment for the…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- EmeraldThunder (NCT02131129)
- Testing
- rTMS
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Diet, Healthy, Psychotic Disorders
Weight Management Program for Patients With First Episode Psychosis
Severe mental illnesses (SMI), such as schizophrenia, are associated with increased morbidity and mortality in large part due to obesity and concomitant metabolic disorders.
- Trial name
- NCT05207982
- Testing
- Family Based weight management program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- State University of New York at Buffalo
Schizophrenia
Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
The goal of this project is to show that the best possible option for preventing relapses in patients suffering from first episode (<1 year of anti-psychotic medication) or early phase (< 5 years of lifetime exposure to…
- Trial name
- PRELAPSE (NCT02360319)
- Testing
- Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation
- Where
- 39 sites in United States
- Volunteers
- 489 people
- Sponsor
- Vanguard Research Group
Schizophrenia, Schizoaffective Disorder
An Integrated Program for the Treatment of First Episode of Psychosis
The purpose of this study is to determine how services should be provided to reduce symptoms and improve life functioning for adolescents and adults who have been recently diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder
- Trial name
- RAISE ETP (NCT01321177)
- Testing
- Integrated Treatment, Community Care
- Where
- 33 sites in United States
- Volunteers
- 404 people
- Sponsor
- Northwell Health
Schizophrenia
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00320671
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Optimizing Response in Psychosis Study
The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
- Trial name
- ORP (NCT00314327)
- Testing
- long-acting injectable risperidone
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwell Health
Schizophrenia, Schizophreniform Disorder
Biomarkers in First Episode Schizophrenia
This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type
- Trial name
- NCT02033382
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Schizophrenia
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00330551
- Testing
- Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta)
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles